RxDoctor Payments Data

Amirpasha Ehsan, MD

Physical Medicine & Rehabilitation · Irvine, CANPI 1790073385

Payments from drug & device makers

$1,237in general payments, 2019–2025

Across 17 payments — averaging $72.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hollister Incorporated$236
  • Johnson & Johnson$172
  • Medtronic$145
  • Flowonix Medical Incorporated$134
  • Lilly USA, LLC$130
  • UCB, Inc.$125
  • plus $296 from 5 others

What the payments were for

  • Travel & lodging$91%
  • Food & beverage$1,22899%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Hollister Incorporated3$236
Johnson & Johnson(2 entities)3$172
Medtronic2$145
Flowonix Medical Incorporated1$134
Lilly USA, LLC2$130
UCB, Inc.1$125
Radius Health, Inc.1$118
Neurometrix Inc1$106
Mallinckrodt Hospital Products Inc.1$30
Amgen1$27
IBSA Pharma Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,237 in reported general payments places this provider in the 75th percentile of 830 physical medicine & rehabilitation providers in California.

See all physical medicine & rehabilitation providers in California

Medicare billing

Part B allowed, 2024
$348,015
Medicare patients
893
Services billed
3,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$20,619
XareltoRivaroxaban62$17,445
Oxtellar XrOxcarbazepine14$8,255
GemtesaVibegron33$7,941
JardianceEmpagliflozin24$6,726
JanuviaSitagliptin Phosphate23$6,473
DapagliflozinDapagliflozin Propanediol12$3,117
TradjentaLinagliptin11$2,640
Lidocaine24$2,325
Divalproex Sodium19$1,625
Gabapentin79$1,215
Memantine Hcl44$1,188
Lactulose26$941
Carbidopa-LevodopaCarbidopa/Levodopa33$926
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate41$906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$172$17,44562 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 830 physical medicine & rehabilitation providers in California.

Other physical medicine & rehabilitation in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →